Anavex Life Sciences (AVXL) Non-Current Deffered Revenue (2021 - 2025)

Anavex Life Sciences (AVXL) has 5 years of Non-Current Deffered Revenue data on file, last reported at $805000.0 in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $805000.0; the trailing twelve-month figure through Dec 2025 stood at $805000.0 (changed N/A YoY), and the FY2025 full-year result was $805000.0, down 4.39% from the prior year.
• Non-Current Deffered Revenue was little changed at $805000.0 in Q4 2025, from $805000.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $917000.0 in Q3 2023 to a low of $443831.0 in Q3 2021.
• A 5-year average of $709471.8 and a median of $805000.0 in 2025 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue soared 106.53% in 2023 and slipped 8.18% in 2024, its largest moves.
• Tracing AVXL's Non-Current Deffered Revenue over 5 years: stood at $443831.0 in 2021, then advanced by 0.04% to $444000.0 in 2022, then jumped by 106.53% to $917000.0 in 2023, then decreased by 8.18% to $842000.0 in 2024, then declined by 4.39% to $805000.0 in 2025.
• Business Quant data shows AVXL's Non-Current Deffered Revenue at $805000.0 in Q4 2025, $805000.0 in Q3 2025, and $842000.0 in Q3 2024.